PRT
PermRock Royalty Trust·Energy
3.00
1.316%(−0.04)
Market ClosedLast Updated: — ET
52W L: $2.6152W H: $4.28
PRT NEWS
prnewswire.com
Mar 20
PermRock Royalty Trust Declares Monthly Cash Distribution
DALLAS, March 20, 2026 /PRNewswire/ -- PermRock Royalty Trust (NYSE: PRT) (the "Trust") today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust ("Trust Units") as of March 31, 2026, and payable on April 14, 2026, in the amount of $36,445.91 ($0.002995 per Trust Unit), based principally upon production during the month of January 2026. The following table displays underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month net profits interest calculations: Underlying Sales Volumes Average Price Oil Natural Gas Oil Natural Gas Bbls Bbls/D Mcf Mcf/D (per Bbl) (per Mcf) Current Month 12,110 391 34,753 1,121 $57.04 $0.79 Prior Month 16,605 536 12,459 402 $56.95 $2.68 Oil cash receipts for the properties underlying the Trust totaled $0.69 million for the current month, a decrease of $0.26 million from the prior month's distribution period.
globenewswire.com
Mar 17
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A selective degrader (PRT13722) has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22.
globenewswire.com
Mar 10
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2 nd half of 2026 Current cash runway expected into second quarter of 2027 with $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025 WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025 and provided an update on its R&D pipeline and other corporate developments.
prnewswire.com
Feb 17
PermRock Royalty Trust Declares Monthly Cash Distribution
DALLAS, Feb. 17, 2026 /PRNewswire/ -- PermRock Royalty Trust (NYSE:PRT) (the "Trust") today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust ("Trust Units") as of February 27, 2026, and payable on March 13, 2026, in the amount of $131,772.12 ($0.010831 per Trust Unit), based principally upon production during the month of December 2025. The following table displays underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month net profits interest calculations: Underlying Sales Volumes Average Price Oil Natural Gas Oil Natural Gas Bbls Bbls/D Mcf Mcf/D (per Bbl) (per Mcf) Current Month 16,605 536 12,459 402 $56.95 $2.68 Prior Month 15,857 529 14,637 488 $57.51 $2.20 Oil cash receipts for the properties underlying the Trust totaled $0.95 million for the current month, an increase of $0.04 million from the prior month's distribution period.
247wallst.com
Feb 5
These $5 Stocks and ETFs Are Paying Huge Yields to 12%, but There's a Catch
While most of Wall Street focuses on large- and mega-cap stocks, which offer safety and liquidity, many investors are constrained in the number of shares they can buy.
globenewswire.com
Feb 3
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs).
